TABLE 2

Concomitant treatments in patients with type 2 diabetes at baseline and on follow-up*

TreatmentBaseline
Follow-up
Ala carriers
Pro/Pro homozygotes
Ala carriers
Pro/Pro homozygotes
OverallACEi yesACEi noOverallACEi yesACEi noOverallACEi yesACEi noOverallACEi yesACEi no
Concomitant medication17791869424644781779186942464478
Glucose-lowering regimen
    Diet alone59 (33.3)31 (34.1)28 (32.6)273 (29.0)130 (28.0)143 (29.9)41 (23.2)21 (23.1)20 (23.3)190 (20.2)92 (19.8)98 (20.5)
    Oral hypoglycemic agent alone97 (54.8)49 (53.8)48 (55.8)555 (58.9)284 (61.2)271 (56.7)101 (57.1)51 (56.0)50 (58.1)586 (62.2)294 (63.4)292 (61.1)
    Insulin and oral hypoglycemic agent14 (7.9)8 (8.8)6 (7.0)58 (6.2)24 (5.2)34 (7.1)30 (17.0)15 (16.5)15 (17.4)112 (11.9)50 (10.8)62 (13.0)
    Insulin alone7 (4.0)3 (3.3)4 (4.7)56 (5.9)26 (5.6)30 (6.3)5 (2.8)4 (4.4)1 (1.2)54 (5.7)28 (6.0)26 (5.4)
Antihypertensive agents
    Any97 (54.8)48 (52.8)49 (57.0)519 (55.1)258 (55.6)261 (54.6)105 (59.3)53 (58.2)52 (60.5)586 (62.2)277 (59.7)309 (64.6)
    Diuretic41 (23.2)19 (20.9)22 (25.6)202 (21.4)95 (20.5)107 (22.4)26 (14.7)14 (15.4)12 (14.0)186 (19.8)78 (16.8)108 (22.6)
    β-blocker14 (7.9)10 (11.0)4 (4.7)76 (8.1)37 (8.0)39 (8.2)16 (9.0)11 (12.1)5 (5.8)81 (8.6)39 (8.4)42 (8.8)
    Calcium-channel blocker (dihydropyridine)40 (22.6)16 (17.6)24 (27.9)274 (29.1)130 (28.0)144 (30.1)47 (26.6)21 (23.1)26 (30.2)262 (27.8)122 (26.3)140 (29.3)
    Sympatholytic agent41 (23.2)16 (17.6)25 (29.1)195 (20.7)107 (23.1)88 (18.4)75 (42.4)34 (37.4)41 (47.7)442 (46.9)193 (41.6)249 (52.1)
Lipid-lowering agents
    Any19 (10.7)9 (9.9)10 (11.6)110 (11.7)58 (12.5)52 (10.9)38 (21.5)16 (17.6)22 (25.6)201 (21.3)99 (21.3)102 (21.3)
    Statin alone11 (6.2)4 (4.4)7 (8.1)70 (7.4)43 (9.3)27 (5.6)23 (13.0)8 (8.8)15 (17.4)141 (15.0)72 (15.5)69 (14.4)
    Fibrate alone5 (2.8)2 (2.2)3 (3.5)35 (3.7)14 (3.0)21 (4.4)5 (2.8)3 (3.3)2 (2.3)39 (4.1)17 (3.7)22 (4.6)
    Statin and fibrate0003 (0.3)1 (0.2)2 (0.4)6 (3.4)2 (2.2)4 (4.7)14 (1.5)8 (1.7)6 (1.3)
Antiplatelet agent5 (2.8)4 (4.4)1 (1.2)22 (2.3)10 (2.2)12 (2.5)18 (10.2)12 (13.2)6 (7.0)70 (7.4)37 (8.0)33 (6.9)
  • Data are n or n (%).

  • *All differences between the two genotype groups (Ala vs. Pro/Pro) were not significant.

  • P < 0.05 vs. ACEi yes. ACEi, ACE inhibitor therapy.